摘要
目的为血液透析患者应用β-内酰胺类药物的安全性提供参考。方法分析1例规律血液透析患者应用注射用哌拉西林钠舒巴坦钠致精神异常的病例,评估药品不良反应发生的可能因素与用药安全性。结果此次药品不良反应与注射用哌拉西林钠舒巴坦钠可能有关,经停药和对症处理后,患者未再出现精神异常。结论肾功能异常患者临床应用注射用哌拉西林钠舒巴坦钠时,需根据内生肌酐清除率(Ccr值)调整给药剂量或给药间隔,以确保临床用药的安全性和有效性,同时警惕中枢神经系统相关严重不良反应的发生。
Objective To provide reference for safe use ofβ-lactam in hemodialysis patients.Methods A case of mental abnormality caused by piperacillin sodium and sulbactam sodium for injection in a regular hemodialysis patient was retrospectively analyzed to find out about the possible causes of adverse drug reactions and the safety of medication.Results The adverse drug reactions might have involved piperacillin sodium and sulbactam sodium for injection.After drug withdrawal and symptomatic treatment,the patient developed no more mental abnormalities.Conclusion The dose or interval of piperacillin sodium and sulbactam sodium for injection should be adjusted according to the endogenous creatinine clearance(Ccr)to ensure the safety and efficacy of medications.Clinicians should be alert to serious adverse reactions related to the central nervous system.
作者
张志文
唐莉华
ZHANG Zhiwen;TANG Lihua(Department of Nephrology,Jiangxi Province Hospital of Integrated Chinese and Western Medicine,Nanchang Jiangxi 330003,China;Department of Pharmacy,Jiangxi Province Hospital of Integrated Chinese and Western Medicine,Nanchang Jiangxi 330003,China)
出处
《中国药物警戒》
2023年第5期588-590,共3页
Chinese Journal of Pharmacovigilance
关键词
哌拉西林钠舒巴坦钠
药品不良反应
尿毒症
精神异常
血液透析
piperacillin sodium and sulbactam sodium
adverse drug reaction
uremia
mental disorder
hemodialysis
